AFSUMB关于使用Sonazoid进行超声造影临床实践的共识声明与推荐
该共识由亚洲超声医学与生物学联合会制定,针对Sonazoid超声造影剂在肝脏及胰胆系统应用中的标准方案与给药方式提出推荐,旨在规范亚洲患者的临床应用并改善患者管理。
要点
- Sonazoid超声造影的共识推荐主要涉及肝脏及胰胆系统应用。
- 共识旨在为亚洲患者建立Sonazoid使用与给药的标准方案。
- 此前指南未主要针对Sonazoid描述,因临床经验仅限于日本和韩国。
核心结论
- 新提出的共识声明与推荐为Sonazoid的使用提供一般性建议,旨在为亚洲患者肝脏及胰胆应用建立标准方案并改善患者管理。
研究设计与样本
- 该文件为亚洲超声医学与生物学联合会(AFSUMB)制定的共识声明与推荐,方法学细节原文未报告。
局限性
- 原文指出此前无主要针对Sonazoid的指南,因临床经验仅局限于日本和韩国。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The first edition of the guidelines for the use of ultrasound contrast agents was published in 2004, dealing with liver applications. The second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some nonliver applications. The third edition of the contrast-enhanced ultrasound (CEUS) guidelines was the joint World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology (WFUMB-EFSUMB) venture in conjunction with other regional US societies such as Asian Federation of Societies for Ultrasound in Medicine and Biology, resulting in a simultaneous duplicate on liver CEUS in the official journals of both WFUMB and EFSUMB in 2013. However, no guidelines were described mainly for Sonazoid due to limited clinical experience only in Japan and Korea. The new proposed consensus statements and recommendations provide general advice on the use of Sonazoid and are intended to create standard protocols for the use and administration of Sonazoid in hepatic and pancreatobiliary applications in Asian patients and to improve patient management.
引用
- Lee JY, Minami Y, Choi BI, et al. The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. J Med Ultrasound. 2020. PMID: 32874864. doi:10.4103/JMU.JMU_124_19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。